pharmaphorum

JUNE 6, 2022

The “middlemen” The individuals or companies within that complicated supply chain are what MCCPDC calls “the middlemen,” namely pharmacy benefit managers (PBM) or group purchasing organisations (GPOs), who can be the source of prescription prices that are substantially higher than market value. About the author.

Drugs 144

Drugs Manufacturing Pharmacy Branding 144

XTalks

JUNE 8, 2022

Novartis’ biosimilars and generics drug division Sandoz has announced a new global campaign called ‘Act4Biosimilars’ to help raise awareness about biosimilars and increase their adoption by at least 30 percent in over 30 countries by the year 2030. billion in 2021 to a high of $44.7 percent.

Generic Pharmaceutical 69

Generic Pharmaceutical Branding Production Medicine 69

XTalks

FEBRUARY 8, 2021

In order to fact-check some of these misconceptions, the US Food and Drug Administration (FDA) recently hosted a webinar on biosimilar and interchangeable biological products to help healthcare professionals understand more about these treatment options. Biosimilars are the “generic” drugs of the biopharma world.

Production 78

Production Insulin Branding Generic Drugs 78

Pharma in Brief

AUGUST 9, 2021

On July 31, 2021, Health Canada published a Notice of Intent outlining its plan to amend the Food and Drug Regulations ( FDR ) and the Medical Devices Regulations in the spring of 2022. Generic drugs and biosimilars are not eligible for this application pathway. Biologic Drugs.

Regulation 98

Regulation Drugs Manufacturing Production 98

Pharma in Brief

JUNE 21, 2020

They include: (1) new factors for assessing excessive pricing, (2) new powers to collect information regarding these factors, (3) new obligations to report indirect price adjustments, (4) risk-based reporting obligations for OTC and generic drugs, and (5) a revised list of international price comparator countries (the PMPRB11 ).

Medicine 40

Medicine Regulation Sales Generic Drugs 40

The Pharma Data

JANUARY 17, 2021

As a bioscience accelerator at the leading-edge of the life science industry, XPhyto will target growth through commercialization of existing products and focused investment in impact driven innovation with the potential for extreme value creation. Drug Formulations and Delivery.

Production 40

Production Drug Delivery Development Drugs 40

Pharma in Brief

JANUARY 9, 2022

Over the past decade, a generic manufacturer has been pursuing claims in the Ontario Superior Court under the Ontario and English Statutes of Monopolies , and other common law causes of action. In two separate summary judgment decisions, the Ontario Superior Court has now dismissed these claims on their merits.

Regulation 52

Regulation Manufacturing Medicine Drugs 52

Drug Discovery World

AUGUST 8, 2023

DDW’s Megan Thomas takes a deeper look into why India is ramping up drug discovery research, and explores the country’s innovation hubs of interest. In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1.

Research 52

Research Drugs Genome Genomics 52

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. billion, reflecting a 19 percent increase, primarily attributed to expanding market presence in China.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Pharmaceutical Technology

JULY 10, 2008

As the blockbuster drugs of the 90s that earned the industry billions reach their patent shelf lives, pharmaceutical companies require new medicines to sustain an estimated $157bn worth of sales. Even so, current figures show firms’ biggest portion of spend is still on marketing and administration at 33.1%,

Medicine 130

Medicine Clinical Trials Clinical Trials Development 130

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. billion, reflecting a 19 percent increase, primarily attributed to expanding market presence in China.

FDA Approval 52

FDA Approval Drugs Sales Development 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JUNE 16, 2023

The current shortage demonstrates how profits in the generic drug market can send shocks through the supply chain, creating a ripple effect that impacts the healthcare system and patients relying on these lifesaving treatments​​.

Drugs 98

Drugs Manufacturing Clinical Supply Chain Clinical Trials 98

The Pharma Data

JANUARY 27, 2021

CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT ) (“ XPhyto ” or the “ Company “) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. In 2020, XPhyto reported significant advancements in four drug formulation development programs.

Drugs 52

Drugs Manufacturing Drug Delivery Production 52

Pharmaceutical Technology

MAY 3, 2023

Since 2015, the US Food and Drug Administration (FDA) has approved more than 450 “first generics” or the first generic equivalent for a branded drug. These medicines comprise about 10% of all generics approved each year. However, that percentage of multiple first generics is not very high—approximately 10.6%

Generic Drugs 246

Generic Drugs Branding Drugs Production 246

XTalks

AUGUST 30, 2022

Whether you are a director, manager or hold a C-suite role within a pharma, biotech, medical device or life science organization, it is important to understand which leadership styles are currently gaining much influence in the industry. When new market disruptions occur, a transformational leadership style can be of great value.

Life Science 105

Life Science Generic Drugs Drug Delivery Compliance 105

XTalks

SEPTEMBER 14, 2020

All this cannot begin to explain the weird reality that the stock markets in the US (and elsewhere) are doing just fine. In fact, financial markets have almost regained most of the losses caused by COVID-19. Here again, the stock markets are functioning in a parallel universe. Drugs and Vaccines. billion in June.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92